Novavax to Participate in the FBR New Prescriptions Conference
April 13 2016 - 4:05PM
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced
Stanley C. Erck, President and Chief Executive Officer, will
participate in a panel discussion at the FBR Healthcare Series
Conference New Prescriptions: Innovation in the Treatment of
Diseases and Infections.
Conference details are as follows:
Date: Wednesday, April 20, 2016Time: 9:30 a.m. U.S. Eastern
TimeLocation: J.W. Marriott Essex House, New York City
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
vaccine company committed to delivering novel products to prevent a
broad range of infectious diseases. Its recombinant nanoparticles
and Matrix-M™ adjuvant technology are the foundation for
ground-breaking innovation that improves global health through safe
and effective vaccines. Additional information about Novavax is
available on the company's website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Sep 2023 to Sep 2024